Trust Signals
- All dose figures trace directly to the Astrup et al. 2008 Phase 2 trial, published in Obesity (Silver Spring), or named follow-up pharmacokinetic studies.
- Tesofensine is not FDA-approved. This page does not promote its use; it describes what published research shows.
- Where evidence is animal-only or mechanism-only, it is labeled as such.
- Competitor claims that are not supported by human data are identified explicitly in the "What Most Pages Get Wrong" section.
- No dose on this page should be self-administered. Physician oversight is required given cardiovascular risk.
Key Takeaways
- The only human Phase 2 RCT tested three doses: 0.25 mg, 0.5 mg, and 1.0 mg once daily for 24 weeks (n=203, Astrup et al., 2008, Obesity (Silver Spring)).
- The 0.5 mg dose produced a mean weight loss of roughly 10 kg over 24 weeks versus approximately 2 kg on placebo in that trial.
- The 1.0 mg dose added little extra weight loss versus 0.5 mg but meaningfully increased heart rate, dry mouth, nausea, and insomnia rates.
- Tesofensine is not a peptide. It is a small-molecule triple monoamine reuptake inhibitor with an unusually long half-life (roughly 220 hours), meaning steady-state accumulates over weeks.
- No Phase 3 data exist. Every compounded protocol today extrapolates from a single 24-week, 203-person trial conducted in Denmark.
What Is the Right Tesofensine Dose?
The best-supported tesofensine dose from human RCT evidence is 0.5 mg once daily. In the only published Phase 2 trial (Astrup et al., 2008, Obesity (Silver Spring), n=203), this dose produced the most favorable efficacy-to-side-effect ratio over 24 weeks. A starting dose of 0.25 mg is used in compounded protocols for 4 to 8 weeks to assess cardiovascular and CNS tolerability before escalation.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What doses were actually tested in humans?
- How does tesofensine produce weight loss at the molecular level?
- Evidence ledger: what confidence should you have in each claim?
- What does a sensible titration schedule look like?
- What do most tesofensine dosage pages get wrong?
- Half-life and accumulation: why the long half-life changes everything
- How does tesofensine compare to semaglutide and other options?
- How to read a tesofensine COA and product label
- Who should not take tesofensine at any dose?
- FAQ
- Sources
What Doses Were Actually Tested in Humans?
The foundational human data comes from one trial: a 24-week, randomized, double-blind, placebo-controlled Phase 2 study by Astrup and colleagues, published in Obesity (Silver Spring) in 2008 (PMID: 18421261). The trial enrolled 203 participants with obesity across three active dose arms and a placebo group, all on a mild caloric deficit.
| Dose | Mean Weight Loss (kg) | Mean Heart Rate Change (bpm) | Dry Mouth Rate |
|---|---|---|---|
| Placebo | ~2.0 kg | Minimal | Low |
| 0.25 mg/day | ~7.2 kg | Small increase | Moderate |
| 0.5 mg/day | ~10.6 kg | Moderate increase | Moderate-high |
| 1.0 mg/day | ~12.8 kg | Larger increase | High |
Weight-loss values above are reported as approximate means from Astrup et al. (2008). Heart rate figures in that paper showed a dose-dependent increase; the specific bpm values for each arm are reported in the original publication and should be consulted directly rather than reproduced here as secondary approximations. The 0.5 mg and 1.0 mg groups both significantly outperformed placebo, but the incremental weight loss from doubling the dose to 1.0 mg was modest while cardiovascular and CNS adverse events increased substantially.
How Does Tesofensine Produce Weight Loss at the Molecular Level?
Tesofensine (molecular formula C17H23ClN2, molecular weight 289.8 g/mol as free base) inhibits the presynaptic reuptake transporters for dopamine (DAT), norepinephrine (NET), and serotonin (SERT). It does not act as a releaser like amphetamine; it blocks reuptake without causing transporter-mediated efflux. This distinction matters for both abuse potential and side-effect profile.
The weight-loss mechanism has two components:
- Appetite suppression via hypothalamic pathways. Elevated synaptic monoamines, particularly dopamine and norepinephrine in the hypothalamus, reduce hunger signaling. Animal studies (Lehr et al., 2008, pharmacokinetic-pharmacodynamic modelling work in rodent models) show reduced food intake at doses proportionally consistent with human trial doses, but the exact hypothalamic nuclei involved and relative contribution of each transporter in humans remain mechanistically extrapolated rather than directly measured.
- Possible increase in energy expenditure. Adrenergic activation from elevated norepinephrine may raise resting metabolic rate. The magnitude in humans at 0.5 mg has not been precisely quantified in a dedicated calorimetry study separate from the Astrup trial. This remains a plausible but unquantified contributor.
Evidence Ledger: What Confidence Should You Have in Each Claim?
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| 0.5 mg causes greater weight loss than placebo at 24 weeks | Single Phase 2 RCT (n=203, Astrup 2008) | Positive, meaningful | Moderate |
| 1.0 mg increases heart rate more than 0.5 mg | Same Phase 2 RCT | Positive (adverse) | Moderate |
| Triple monoamine reuptake inhibition drives appetite suppression | Pharmacology + animal models | Positive (mechanistic) | Low (mechanism only) |
| Tesofensine raises resting energy expenditure in humans | Inferred from adrenergic pharmacology | Plausible, unquantified | Very Low |
| Long-term (beyond 24 weeks) weight maintenance | No human data | Unknown | Very Low |
| Combination with GLP-1 agonists is safe | No human data | Unknown | Very Low |
| Half-life approximately 220 hours supports once-daily dosing | Human PK data (Lehr et al. 2008) | Confirmed | Moderate |
What Does a Sensible Titration Schedule Look Like?
The Astrup trial did not titrate. Participants were randomized directly to their assigned dose. The titration approach used in current compounded protocols is a clinical extrapolation designed to manage side effects, not a protocol validated in a separate trial. Understand that distinction before following any titration chart.
| Week | Dose | Purpose |
|---|---|---|
| 1 to 4 | 0.25 mg/day | Assess cardiovascular and CNS tolerability; establish baseline heart rate and blood pressure |
| 5 to 8 | 0.25 mg/day (continued) | Continue if heart rate has increased substantially or symptoms are present; titrate up if stable |
| Week 5 or 9 (if tolerated) | 0.5 mg/day | Target maintenance dose based on Phase 2 data |
| Ongoing | 0.5 mg/day | Do not escalate to 1.0 mg without documented clinical justification |
What Do Most Tesofensine Dosage Pages Get Wrong?
This is the section commodity pages skip entirely. Here are the four most common inaccuracies:
1. Calling it a peptide
Tesofensine is not a peptide. It contains no amino acid chain, no peptide bond, and no characteristics that define a peptide. It is a bicyclic morpholine derivative and a small-molecule drug. The "tesofensine peptide" phrasing is a marketing label, almost certainly used to circumvent advertising restrictions on stimulant-adjacent compounds. The chemistry is unambiguous.
2. Citing a "standard dose" of 0.5 mg as universally validated
The 0.5 mg finding comes from one 203-person trial. That is not a validated standard; it is the best available signal. No dose-ranging study in populations with type 2 diabetes, cardiovascular disease, or on polypharmacy has been conducted.
3. Omitting accumulation risk during the first few weeks
Because tesofensine's half-life is roughly 220 hours (approximately 9 days), it takes 5 to 7 half-lives, or roughly 6 to 10 weeks, to reach steady-state plasma concentration. A person who starts at 0.25 mg and escalates at week 4 is escalating before the first dose's tissue distribution has fully plateaued. Adverse effects may emerge or worsen at week 5 to 8 even without a dose change.
4. Presenting weight-loss figures without diet context
All Astrup trial participants were on a caloric deficit diet. The roughly 10 kg loss at 0.5 mg is not a drug-only effect. Diet adherence was controlled and monitored. Extrapolating this figure to uncontrolled real-world use overstates expected outcomes.
Half-Life and Accumulation: Why the Long Half-Life Changes Everything
Tesofensine's elimination half-life in humans is approximately 220 hours, making it one of the longest-acting small-molecule CNS drugs in this class. For comparison, bupropion's half-life is in the range of roughly 20 hours and phentermine's is similar. The pharmacokinetic consequence is important for dosing practice.
At once-daily dosing, plasma concentrations accumulate progressively for approximately 6 to 10 weeks before reaching a true steady state. This means:
- Side effects that were tolerable in week 2 may worsen in week 6 to 8 without any dose change, because trough levels are still rising.
- If a dose is missed, no single missed day causes a meaningful drop in plasma level. This supports adherence flexibility but also means the drug cannot be quickly discontinued if adverse events occur.
- Washout after stopping takes many weeks, not days. Interactions with MAOIs, for example, represent a prolonged risk window after discontinuation.
How Does the Tesofensine Dose Compare to Approved and Established Alternatives?
| Compound | Class | Approval Status | Mean Weight Loss (best RCT) | Trial Size | Trial Duration | Key Advantage | Key Disadvantage vs Tesofensine |
|---|---|---|---|---|---|---|---|
| Tesofensine 0.5 mg/day | Triple reuptake inhibitor | Not approved | ~10 kg (Astrup 2008) | 203 | 24 weeks | Strong early appetite suppression | No Phase 3 data, not approved |
| Semaglutide 2.4 mg/week (Ozempic/Wegovy) | GLP-1 agonist | FDA-approved (obesity) | ~15% body weight (Wilding et al. 2021) | 1,961 | 68 weeks | Extensive safety data, approved | GI side effects, injectable, cost |
| Phentermine-topiramate ER (Qsymia) | Sympathomimetic + anticonvulsant | FDA-approved | ~10% body weight (Gadde et al. 2011) | ~2,500 | 56 weeks | Oral, well-studied | Teratogenic risk, cognitive side effects |
| Bupropion-naltrexone (Contrave) | Dopamine/NE reuptake inhibitor + opioid antagonist | FDA-approved | ~6% body weight (Greenway et al. 2010) | 1,742 | 56 weeks | Oral, approved, depression benefit | Lower weight loss magnitude |
Tesofensine loses on regulatory status and evidence depth to all three approved comparators. It wins on ease of once-daily dosing and possibly on early appetite-suppression magnitude, but those advantages rest on a single trial. A skeptical clinician will note that semaglutide's evidence base is roughly 10 times larger by participant count and roughly three times longer by trial duration.
How to Read a Tesofensine COA and Product Label
Because tesofensine is not FDA-approved, products arrive as compounded medications or research-use capsules. Label literacy protects you from substandard material.
What a credible COA must contain
- HPLC purity at or above 98%. Purity stated only by mass spec (LCMS identity confirmation) without an HPLC area-percentage purity figure is insufficient. MS confirms identity; HPLC quantifies purity.
- Correct molecular weight. Tesofensine free base: 289.8 g/mol. As the mesylate salt (a common pharmaceutical form): different mass. Confirm which form you have and that the listed MW matches.
- Endotoxin or LAL testing, especially for any injectable adjacent use.
- Heavy metals panel (lead, arsenic, cadmium, mercury) if the compound was synthesized offshore.
Stability and storage
Tesofensine is a small organic molecule, not a protein. It does not require freezing. Most compounded oral capsules are stable at room temperature when protected from moisture and light. However, compounded formulations using carriers or fillers that interact with moisture can degrade the active ingredient faster than the raw compound would alone. A legitimate compounding pharmacy will provide a beyond-use date consistent with USP Chapter 795 stability data, not simply the maximum allowed window.
Reconstitution math (for research formulations)
If you receive tesofensine powder and need to prepare a solution for research use: to achieve a 0.5 mg/mL concentration in a vehicle, dissolve 50 mg in 100 mL of your vehicle. Confirm final concentration by HPLC if downstream dosing precision is required. Label with preparation date, concentration, vehicle, and storage conditions.
Who Should Not Take Tesofensine at Any Dose?
Based on its pharmacology (triple monoamine reuptake inhibition) and the Astrup trial exclusion criteria, the following groups carry the highest risk and were excluded from or contraindicated in relevant research:
- Current MAOI users. Combining any monoamine reuptake inhibitor with an MAOI risks serotonin syndrome, which can be life-threatening. Given tesofensine's approximately 220-hour half-life, the washout period before MAOI use is extended substantially.
- Uncontrolled hypertension (systolic above 160 mmHg or diastolic above 100 mmHg).
- History of cardiac arrhythmia, particularly supraventricular tachycardia.
- Active or recent history of stimulant use disorder (dopamine transporter occupancy parallels stimulant pharmacology).
- Pregnancy. No safety data exist; monoaminergic drugs as a class carry fetal risk signals.
- Concurrent use of strong CYP3A4 inhibitors without dose adjustment guidance (which currently does not exist in any approved labeling).
FAQ
What is the clinical trial tesofensine dose range?
The Phase 2 NeuroSearch trial (Astrup et al., 2008, published in Obesity (Silver Spring)) tested 0.25 mg, 0.5 mg, and 1.0 mg once daily for 24 weeks. The 0.5 mg dose produced the best risk-benefit profile, yielding roughly 10 kg mean weight loss versus about 2 kg on placebo.
Is tesofensine approved by the FDA?
No. Tesofensine has not received FDA approval for any indication as of 2026. It was investigated as an orphan drug for Parkinson's and Alzheimer's disease before being repurposed for obesity research. It is available only as a research or compounded formulation.
What starting dose is used in compounded tesofensine protocols?
Compounded clinical protocols commonly begin at 0.25 mg daily for 4 to 8 weeks to assess cardiovascular and CNS tolerability before titrating to 0.5 mg. These protocols are not FDA-approved and are based on the 2008 Phase 2 data.
Why is the 1.0 mg tesofensine dose generally avoided?
In Astrup et al. (2008), the 1.0 mg group showed significantly higher rates of dry mouth, nausea, constipation, and insomnia, along with a meaningfully greater heart rate increase compared to the 0.5 mg group. The added weight loss did not justify the added cardiovascular and CNS burden.
Is tesofensine a peptide?
No. Tesofensine is a small-molecule triple monoamine reuptake inhibitor, not a peptide. It inhibits reuptake of dopamine, norepinephrine, and serotonin. The "tesofensine peptide" label seen in some marketing is chemically inaccurate.
How long does tesofensine take to show weight-loss effect?
In the 24-week Astrup trial, the 0.5 mg group showed meaningful weight separation from placebo within the first several weeks, with the majority of loss occurring in the first 12 weeks. Weight loss continued but at a slower rate through week 24.
What is tesofensine's half-life and how does that affect dosing?
Tesofensine has a long half-life reported in the range of approximately 220 hours (roughly 9 days) in human pharmacokinetic data, which supports once-daily dosing and means that accumulation occurs over multiple weeks before steady state is reached.
Can tesofensine be combined with GLP-1 agonists?
There are no published human RCTs examining tesofensine plus GLP-1 agonist combinations as of 2026. Mechanistic rationale exists (complementary pathways), but additive cardiovascular and CNS effects are an unstudied risk. This combination should only occur under direct physician supervision.
What does a degraded or low-quality tesofensine product look like on a COA?
A credible COA should show HPLC purity at or above 98%, confirm molecular weight of 289.8 g/mol for the free base (or corresponding salt form weight), and include endotoxin testing. Missing HPLC data or purity stated only by mass spectrometry alone is a red flag.
Who should not use tesofensine at any dose?
Based on its mechanism, individuals with uncontrolled hypertension, a history of cardiac arrhythmia, current MAOI use, or a history of stimulant abuse carry the highest risk. These contraindications mirror those for other monoamine reuptake inhibitors and were exclusion criteria in clinical trials.
How does the tesofensine dose compare to semaglutide for weight loss?
Semaglutide 2.4 mg weekly (STEP 1 trial, Wilding et al. 2021) produced mean body weight reduction of approximately 14.9% over 68 weeks in a large RCT of 1,961 participants. Tesofensine 0.5 mg produced roughly 10 kg over 24 weeks in a 203-participant trial. Direct comparison is limited by different trial durations and populations.
Sources
- Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, Larsen TM. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease. Obesity (Silver Spring). 2008;16(6):1363-1369. PubMed PMID: 18421261.
- Lehr T, Staab A, Tillmann C, et al. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokinetic-pharmacodynamic modelling approach. Br J Pharmacol. 2008;153(1):164-174.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
- Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341-1352.
- Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605.
- FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). U.S. Food and Drug Administration. Accessed 2026. (Tesofensine not listed.)
- USP Chapter 795. Pharmaceutical Compounding: Nonsterile Preparations. United States Pharmacopeia. 2023 revision.
Footer Disclaimers
Platform: This page is published by FormBlends for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendation.
Research Compound / Compounded Medication: Tesofensine is not approved by the U.S. Food and Drug Administration for any indication. Where available, it is sold as a research chemical or compounded medication. Compounded formulations are not FDA-reviewed for safety, efficacy, or quality. Use outside a supervised clinical or research context is the sole responsibility of the individual.
Results: Weight-loss figures cited on this page are means from specific clinical trials under controlled dietary conditions. Individual results vary and may differ substantially from published trial averages.
Trademark: Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Qsymia is a registered trademark of Vivus, Inc. Contrave is a registered trademark of Currax Pharmaceuticals LLC. FormBlends has no affiliation with these companies.